about
The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-AnalysisKinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis BPros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.The Role of Interferon in Hepatitis B Therapy.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patientsSystematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patientsResponse-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Predictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study.Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?Recent advances in the treatment of chronic hepatitis B.Emerging pipeline drugs for hepatitis B infection.HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy.Prediction of spontaneous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients during the immune clearance phase.Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha.Characterization of hepatitis B virus molecular genotypes in Chongqing and quantitative serological markers in patients during natural phases of chronic hepatitis B infection.Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant
P2860
Q28079550-C4C17B4D-FF53-4B0B-81DF-B3A3DA10B9ACQ33721394-9C18580F-2239-462D-9191-6592C34115EDQ33819124-5B2A7119-7F42-402C-9ED5-58E300579798Q34154958-466CF1F5-80EA-4929-84C1-C3E54F32DF08Q34409132-9F89570F-EFA5-443C-9426-F35332DF8AFAQ34505113-B10919A0-146F-470D-BFBC-E3C73C052792Q34594403-226C9C78-92F8-47AC-BA93-10061A443449Q34623662-C37D493D-AC1F-489D-9695-6BEF7490DD5FQ34959519-D1C6D539-3652-42D1-8C20-E4FE078957F9Q35688409-BE4E94D5-6018-4A0C-BE16-063C6C660FA7Q36091371-DE39DC1E-38D9-441F-A8C2-A6785454967DQ36153775-21B82159-AE44-4998-A4C9-1346C39BC646Q37540212-E9F48113-F384-45C5-90D9-C7A5FD5EFB5BQ37696844-E4DDD711-9AA9-4897-A3DD-582F20D2F272Q37825532-28BA157D-1AF4-46D2-9645-A59CADD30B74Q37891094-2891EA98-71B6-48BB-B18D-C4D82428CE8FQ37971052-78650C34-717E-42F9-9794-3CB13708AD24Q38174259-AB1C5828-3F56-491C-82C2-C3F42E4599BEQ39707885-8BD7F29F-9472-48FD-9A6D-B3D2F8FF89C9Q40152820-3E5B9F0C-AD88-4EEC-AB34-CE8A41B4E122Q41730134-CC8FF14C-6E5F-4348-8414-B03E67FB4CBEQ42202189-E3ACA263-3D82-48F0-84BF-C48582B5AE2AQ42203898-DCD24D8B-3226-49C9-BF30-F131E5BEDF23Q42271127-B94EAD9D-7C79-4CD9-8756-05FA8DB7C1C4Q42588946-D645597F-689C-4421-8669-6F7814392028Q42616157-09F8295D-09A3-4B04-A36B-95B8FD404718Q43077705-C4DD5CA1-761A-49A7-8123-72E206D97F3CQ43553454-4DFD3A6D-8DEC-4DA0-B0FB-645001AEB509Q57824837-A9F4B5D6-B5AF-4386-9C92-32A488499701
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endpoints of therapy in chronic hepatitis B.
@en
Endpoints of therapy in chronic hepatitis B.
@nl
type
label
Endpoints of therapy in chronic hepatitis B.
@en
Endpoints of therapy in chronic hepatitis B.
@nl
prefLabel
Endpoints of therapy in chronic hepatitis B.
@en
Endpoints of therapy in chronic hepatitis B.
@nl
P2093
P356
P1433
P1476
Endpoints of therapy in chronic hepatitis B.
@en
P2093
David K H Wong
E Jenny Heathcote
Jordan J Feld
P2860
P304
P356
10.1002/HEP.22977
P407
P433
P577
2009-05-01T00:00:00Z